Clinical Trial Update: A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment [Phase 2]

View source ↗

Summary

Pfizer is running a Phase 2 study of PF-07220060 in combination with Fulvestrant for HR-positive, HER2-negative advanced or metastatic breast cancer that progre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• PF-07220060

Snippet

Sponsor: Pfizer | Conditions: Advanced or Metastatic Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING